CLINICAL TRIALS PROFILE FOR CADUET

All Clinical Trials for CADUET

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00150384 ↗	Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population	Completed	Pfizer	Phase 4	2004-07-01	The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
NCT00150384 ↗	Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	2004-07-01	The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
NCT00332761 ↗	Caduet in an Untreated Subject Population	Completed	Pfizer	Phase 4	2006-06-01	The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
NCT00332761 ↗	Caduet in an Untreated Subject Population	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	2006-06-01	The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
NCT00407537 ↗	Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors	Completed	Pfizer	Phase 4	2007-03-01	To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
NCT00407537 ↗	Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	2007-03-01	To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
NCT00412113 ↗	A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk	Completed	Pfizer	Phase 4	2007-01-01	The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.

Clinical Trial Conditions for CADUET

Condition Name

Condition Name for CADUET
Intervention	Trials
Hypertension	7
Hypercholesterolemia	3
Dyslipidemia	3
Healthy	2

Condition MeSH

Condition MeSH for CADUET
Intervention	Trials
Hypertension	5
Dyslipidemias	4
Hypercholesterolemia	3
Angina Pectoris	2

Clinical Trial Locations for CADUET

Trials by Country

Trials by Country for CADUET
Location	Trials
United States	66
Japan	8
Mexico	4
Venezuela	3
Korea, Republic of	3

Trials by US State

Trials by US State for CADUET
Location	Trials
Ohio	3
New Jersey	3
Missouri	3
Michigan	3
Georgia	3

Clinical Trial Progress for CADUET

Clinical Trial Phase

Clinical Trial Phase for CADUET
Clinical Trial Phase	Trials
Phase 4	9
Phase 1	2

Clinical Trial Status

Clinical Trial Status for CADUET
Clinical Trial Phase	Trials
Completed	9
Unknown status	3
Terminated	1

Clinical Trial Sponsors for CADUET

Sponsor Name

Sponsor Name for CADUET
Sponsor	Trials
Pfizer	8
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	7
Dr. Reddy's Laboratories Limited	2

Sponsor Type

Sponsor Type for CADUET
Sponsor	Trials
Industry	17
Other	5